Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-018-0270-7
Abstract: BackgroundTo our knowledge, inclisiran was the first agent composed of small interfering RNAs (siRNAs) to be preliminarily used to reduce proatherogenic lipoprotein cholesterol levels. Inclisiran was evaluated in large clinical trials but did not receive… read more here.
Keywords: inclisiran 100; randomized controlled; analysis; cholesterol ... See more keywords
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
Sign Up to like & getrecommendations! Published in 2020 at "PharmacoEconomics"
DOI: 10.1007/s40273-020-00948-w
Abstract: Background Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9). The comparison of inclisiran with statin versus statin alone in the ORION-10 trial demonstrated significant reductions in low-density lipoprotein cholesterol (LDL-C). Our study… read more here.
Keywords: analysis; statin; therapy; cardiovascular disease ... See more keywords
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Sign Up to like & getrecommendations! Published in 2022 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehac615
Abstract: Abstract Aims Patients often require combination therapies to achieve LDL cholesterol (LDL-C) targets for the primary prevention of atherosclerotic cardiovascular disease. This study investigates the effect of inclisiran, a small interfering ribonucleic acid targeting hepatic… read more here.
Keywords: day; change; inclisiran; placebo ... See more keywords
Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
Sign Up to like & getrecommendations! Published in 2022 at "Cardiovascular Therapeutics"
DOI: 10.1155/2022/8129513
Abstract: As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide. In contrast to conventional pharmacotherapy, human monoclonal… read more here.
Keywords: targeting pcsk9; disadvantages inclisiran; small interfering; inclisiran ... See more keywords